Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.


Related Content

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst